Clinical and Molecular Hepatology

Search

Close

Most cited

Most-cited are based on citations from 2021 ~ 2023.

Guideline KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho
Clin Mol Hepatol. 2021;27(3):363-401.
Reviews From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clin Mol Hepatol. 2021;27(2):257-269.
Original Articles Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk
Clin Mol Hepatol. 2021;27(1):110-124.
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon
Clin Mol Hepatol. 2021;27(1):157-174.
Reviews The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future
Yusuke Watanabe, Atsunori Tsuchiya, Shuji Terai
Clin Mol Hepatol. 2021;27(1):70-80.
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Erica Jennison, Christopher D. Byrne
Clin Mol Hepatol. 2021;27(1):22-43.
Current understanding of primary biliary cholangitis
Atsushi Tanaka
Clin Mol Hepatol. 2021;27(1):1-21.
Recent updates on the management of autoimmune hepatitis
Atsumasa Komori
Clin Mol Hepatol. 2021;27(1):58-69.
Original Articles Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry
Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim
Clin Mol Hepatol. 2021;27(3):451-462.
Reviews Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
Clin Mol Hepatol. 2021;27(3):402-412.
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2021;27(2):221-235.
Original Articles Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng
Clin Mol Hepatol. 2022;28(3):483-496.
Reviews Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura, Hideki Iwamoto
Clin Mol Hepatol. 2021;27(2):236-245.
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Gwyneth Soon, Aileen Wee
Clin Mol Hepatol. 2021;27(1):44-57.
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):150-163.
Original Articles The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah
Clin Mol Hepatol. 2022;28(3):565-574.
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
Chung-Feng Huang, Pey-Fang Wu, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Hung-Yin Liu, Ying-Chou Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Clin Mol Hepatol. 2021;27(1):136-143.
Reviews Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):790-801.
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma
Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng
Clin Mol Hepatol. 2021;27(4):524-534.
Recent advances in nonalcoholic fatty liver disease metabolomics
Hwi Young Kim
Clin Mol Hepatol. 2021;27(4):553-559.
Original Articles Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Jeong Won Jang, Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Lewis R. Roberts
Clin Mol Hepatol. 2021;27(1):207-218.
Reviews Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho
Clin Mol Hepatol. 2022;28(1):17-30.
Changes in the epidemiology and management of bacterial infections in cirrhosis
Salvatore Piano, Marta Tonon, Paolo Angeli
Clin Mol Hepatol. 2021;27(3):437-445.
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):408-424.
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada
Clin Mol Hepatol. 2021;27(3):413-424.
Original Articles Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed
Clin Mol Hepatol. 2021;27(3):486-498.
Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study
Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park
Clin Mol Hepatol. 2021;27(1):144-156.
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo
Clin Mol Hepatol. 2021;27(4):589-602.
Snapshot Hepatocellular carcinoma statistics in South Korea
Young Eun Chon, Soung Won Jeong, Dae Won Jun
Clin Mol Hepatol. 2021;27(3):512-514.
Reviews Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
Pil Soo Sung
Clin Mol Hepatol. 2022;28(3):333-350.

Go to Top